Dept of Microbiology, L & T Microbiology Research Centre, Vision Research Foundation, Sankara Nethralaya, Chennai, Tamil Nadu, India; School of Chemical & Biotechnology, SASTRA University, Thanjavur, Tamil Nadu, India.
Dept of Microbiology, L & T Microbiology Research Centre, Vision Research Foundation, Sankara Nethralaya, Chennai, Tamil Nadu, India.
Kaohsiung J Med Sci. 2018 Feb;34(2):79-88. doi: 10.1016/j.kjms.2017.09.010. Epub 2017 Nov 6.
Pseudomonas aeruginosa (P. aeruginosa) is a menacing opportunistic, nosocomial pathogen; become a growing concern as conventional antimicrobial therapy is now futile against it. Multi-drug resistant P. aeruginosa (MDRPA) has distinctive resistance mechanisms such as production of β-lactamases, repression of porin genes and over-expression of efflux pumps. The focus of this study is to standardize and application of multiplex PCR (mPCR) to detect the presence of betalactamase genes encoding bla, bla, bla, bla, bla, bla, bla, AmpC and Efflux pump genes encoding Mex A,B-oprM, Mex C,D-oprJ, Mex X,Y-oprN, oprD, nfxB, MexR. A total of 200 clinical isolates of P. aeruginosa were tested for the presence of the above mentioned genes genotypically through mPCR and characterized by phenotypic methods for ESBL and MBL production. Out of 200 isolates, 163 (81.5%) nfxB regulator gene, 102 (51%) MexA, 96 (48%) MexC, 93 (46.5%) MexB, 86 (43%) MexD, 81 (40.5%) OprM, 74 (37%) OprJ, 72 (36%) OprD and MexR, 53 (26.5%) Mex X and OprN, 49 (24.5%) MexY gene. Betalactamase genes 145 (72.5%) bla, 67 (33.5%) bla 35 (17.5%) blaVim, 25(12.50%), 23 (11.50%) blaVeb, 21 (11.5%) blaGes, 14 (7%) Ctx-m and 10 (5%) AmpC and 5 (2.5%) blaDim-1 gene were tested positive by mPCR. Phenotypically 38 (19%) and 29 (14.5%) out of 200 tested positive for ESBL and MBL production. Application of this mPCR on clinical specimens is fast, accurate, specific and low-cost reliable tool for the screening, where culture negative Eubacterial PCR positive cases for an early molecular detection of drug resistance mechanism assisting the clinician to treat the disease with appropriate antibiotic selection.
铜绿假单胞菌(P. aeruginosa)是一种威胁性的机会性病原体,由于常规的抗菌治疗对其无效,因此越来越受到关注。多药耐药铜绿假单胞菌(MDRPA)具有独特的耐药机制,例如产生β-内酰胺酶、抑制孔蛋白基因的表达和过度表达外排泵。本研究的重点是标准化和应用多重 PCR(mPCR)来检测编码 bla、bla、bla、bla、bla、bla、bla、AmpC 的β-内酰胺酶基因和编码 MexA、B-oprM、MexC、D-oprJ、MexX、Y-oprN、oprD、nfxB、MexR 的外排泵基因的存在。通过 mPCR 对 200 株临床分离的铜绿假单胞菌进行了上述基因的基因型检测,并通过表型方法对 ESBL 和 MBL 的产生进行了特征分析。在 200 株分离株中,nfxB 调节剂基因 163 株(81.5%)、MexA 基因 102 株(51%)、MexC 基因 96 株(48%)、MexB 基因 93 株(46.5%)、MexD 基因 86 株(43%)、OprM 基因 81 株(40.5%)、OprJ 基因 74 株(37%)、OprD 基因 72 株(36%)和 MexR 基因 53 株(26.5%)、MexX 和 OprN 基因 53 株(26.5%)、MexY 基因 49 株(24.5%)。β-内酰胺酶基因 bla 145 株(72.5%)、bla 67 株(33.5%)、blaVim 35 株(17.5%)、blaVeb 25 株(12.50%)、blaGes 23 株(11.50%)、Ctx-m 21 株(11.5%)和 AmpC 基因 10 株(5%)、blaDim-1 基因 5 株(2.5%)通过 mPCR 检测为阳性。200 株中 38 株(19%)和 29 株(14.5%)表型上对 ESBL 和 MBL 的产生呈阳性。该 mPCR 应用于临床标本快速、准确、特异、成本低,是一种可靠的筛选工具,对培养阴性、细菌 PCR 阳性的病例进行早期分子耐药机制检测,有助于临床医生选择合适的抗生素进行治疗。